Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$17.41 USD
-0.11 (-0.63%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $17.42 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VRDN 17.41 -0.11(-0.63%)
Will VRDN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRDN
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
MannKind (MNKD) Matches Q3 Earnings Estimates
Other News for VRDN
Viridian partners with Japanese firm for Veligrotug and VRDN-003
Viridian Therapeutics (VRDN) Partners with Kissei for Japanese Market Expansion
Viridian enters veligrotug, VRDN-003 collaboration and license pact with Kissei
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical ...
VRDN Crosses Above Key Moving Average Level